Girard Sharp appointed Co-Lead Counsel in Lidoderm Antitrust Litigation
Girard Sharp has been appointed co-lead counsel in the pending class action lawsuit related to Lidoderms’ unfair marketing and pricing of its lidocaine patch. On May 23, 2014, the Honorable William H. Orrick of the United Stated District Court of the Northern District of California appointed the firm, along with Cohen Milstein Sellers & Toll PLLC and Heins Mills &Y Olson PLC, to serve as co-lead for the proposed End-Payor Class in the Lidoderm Antitrust Litigation.
As co-lead, Girard Sharp will manage the efforts of plaintiffs’ attorneys with respect to all discovery proceedings, briefing and argument of all motions, and communications with defendants’ counsel.
The Lidoderm Antitrust Litigation is brought on behalf of plaintiffs who indirectly purchased, reimbursed or otherwise paid for lidocaine patch 5%, sold under the brand name Lidoderm. Lidoderm is a lidocaine-containing pain patch for the treatment of pain associated with post-herpetic neuralgia.